Could a diabetes drug tame the immune system in kidney disease?

NCT ID NCT07096986

Not yet recruiting Disease control Sponsor: Centre Hospitalier Universitaire de Nice Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether dapagliflozin, a drug used for diabetes and heart failure, can reduce harmful antibodies and prevent relapses in people with membranous nephropathy, an autoimmune kidney disease. The study enrolls 20 adults who have had a recent rise in anti-PLA2R1 antibodies after a period of remission. Participants take dapagliflozin daily for 6 months, and researchers measure changes in antibody levels and protein in the urine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (Forxiga)
What this could lead to: If it works, dapagliflozin could offer a new way to control autoimmune kidney disease and reduce relapses without heavy immunosuppression.
What could go wrong: This is a small, early-phase trial with only 20 participants. The drug's immune effects in this disease are unproven, and it may not reduce antibodies or prevent relapses as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLOMERULONEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glomerulonephritis membranous glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLOMERULONEPHRITIS

Contacts and locations

Locations

CHU de NICE

Nice, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.